Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study. - Wikidata - awgldk - TriplyDB

Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study.

Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study.

http://www.wikidata.org/entity/Q35185694

about

Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology Opposing effects of Apoe/Apoa1 double deletion on amyloid-β pathology and cognitive performance in APP mice.Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease: A Cross-Sectional Study.Meditation and vacation effects have an impact on disease-associated molecular phenotypes.Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ40 and Aβ42 Peptides in Plasma.Identifying biomarkers of dementia prevalent among amnestic mild cognitively impaired ethnic female patients.Increasing Precision of Clinical Diagnosis of Alzheimer's Disease Using a Combined Algorithm Incorporating Clinical and Novel Biomarker Data.Association of amine biomarkers with incident dementia and Alzheimer's disease in the Framingham Study.Whole exome sequence-based association analyses of plasma amyloid-β in African and European Americans; the Atherosclerosis Risk in Communities-Neurocognitive Study.Alzheimer's Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid.Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals.Computational integration of nanoscale physical biomarkers and cognitive assessments for Alzheimer's disease diagnosis and prognosis.Amyloid-β and tau complexity - towards improved biomarkers and targeted therapies.Plasma Amyloid-β Levels, Cerebral Small Vessel Disease, and Cognition: The Rotterdam Study.Plasma amyloid beta peptides: an Alzheimer's conundrum or a more accessible Alzheimer's biomarker?Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic.Plasma Amyloid Is Associated with White Matter and Subcortical Alterations and Is Modulated by Age and Seasonal Rhythms in Mouse Lemur Primates.Vitamin D Supplementation Appears to Increase Plasma Aβ40 in Vitamin D Insufficient Older Adults: A Pilot Randomized Controlled Trial.Elevation of the Plasma Aβ40/Aβ42 Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease.Plasma amyloid-β levels, cerebral atrophy and risk of dementia: a population-based study.Aging and are determinative factors of plasma A42 levels

P2860

Q26774743-316C8CFF-2349-4C1B-8AC8-18B90011606C Q30703354-0250EC95-1620-4604-A824-E5DBD17613CA Q34482760-155AC4D5-035A-44F0-B3B0-9E10AF52317C Q34538942-2E0D1284-1121-4510-8438-C30CCFC775BF Q37300264-4C0CDCDD-3EAA-402F-A359-9B5E8554ACFF Q37346081-3F82DC95-DBB1-4DF4-A3D6-6D34F8A85451 Q38666998-FDDF3BCD-6BC1-4D88-8EEC-F33B5461926A Q38672291-4B7C00D9-E53E-47F3-AF86-00040D5BB71E Q38680904-EA7DA4E5-D212-4955-BAAB-6897D908A1F5 Q39217840-106C2583-71CF-4B31-BFA8-99FC678C5A4C Q41690745-75404FAF-8CB9-414D-849B-2AB2ABBBD780 Q41845239-B8755E66-6868-4D94-8111-D1DD649BF6C3 Q46240783-8C926751-8038-48CE-ACF0-2A96354A5587 Q48031219-72342308-8EFD-4CDE-938B-7F3FF25522F1 Q48605183-5622AA6C-E4A7-4E77-A2F5-C2A1F0FCE42B Q49135523-97E0FD7E-D9C1-44F6-8987-8095B4E77614 Q50354591-81A76F23-6436-4677-9E64-0F02E3139EAA Q52142977-2429E63E-5909-46F5-A1D8-309212CCFE39 Q52148328-BD714528-8689-4811-A450-45EA05D97DCB Q55516241-26C02E4F-1CAF-42C9-9794-9A05CB12A1BC Q57822409-1E22B602-A161-4419-8CF7-67B911269EEC

P2860

Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study.

http://www.wikidata.org/entity/Q35185694

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study.

@ast

Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study.

@en

type

label

Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study.

@ast

Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study.

@en

prefLabel

Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study.

@ast

Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study.

@en

P1433

Q35185694-E3B41D87-7E69-494C-8231-5A4180BDE642

P1476

Q35185694-CE95BA2E-9A0F-4667-8B28-237D122B9957

P2093

Q35185694-0F8FAD73-0E41-4595-A3B3-8A97C8FCF79B

Q35185694-7122E7E9-0457-41C6-B67A-6DFBBA75CAE4

Q35185694-836E2119-965D-41DA-9CC1-780BF33A7A39

Q35185694-86A79521-957F-4CE4-9E14-5F00B6ED09EE

Q35185694-A5180204-5CC3-4E1F-B051-775CD9532DBD

Q35185694-D1D92B60-8106-42E5-BD32-9BC91C1F5376

Q35185694-D74BFDD9-F9E5-469F-B6A2-E35261BCD192

Q35185694-DB884CC1-B736-4663-BFDC-8512D906A54E

P2860

Q35185694-01111566-5D53-40C1-B318-485A64309F9D

Q35185694-073C7E32-EEE5-49BF-B08C-A9D5F3D1FEFD

Q35185694-09091E36-0118-43D1-8937-8B1ABC169110

Q35185694-1ECE423F-C606-4316-AF7B-23010CA418D8

Q35185694-20871B13-4DD0-4714-968D-B05657F177F2

Q35185694-25563EFB-15C7-4DFE-B1C7-B71341C978B1

Q35185694-255EC0F6-5678-41A3-825D-FF443CCF2FA9

Q35185694-295A83B6-0129-4414-89FE-27F4DC6C4025

Q35185694-29FBCF84-E6EB-46B7-9BA8-2C4C1B505121

Q35185694-2C243BA5-1CB7-4458-AEFD-C324C82BCEBB

P304

Q35185694-A27004D1-13D0-4A03-8CF7-0B0345AB4FB6

P31

Q35185694-343A248E-8ABB-49B3-91EC-E75D37468D76

Q35185694-ed2a4d60-3a00-4b69-aa9b-ccaefa94c4b6

P356

Q35185694-5451688D-4BB3-4713-86F2-99160EC31993

P433

Q35185694-89E7314C-D5F8-45D8-BA65-8D1959BC1980

P478

Q35185694-ADB3E039-3BC0-4D42-8D39-1983B48F3585

P50

Q35185694-0996BE79-960A-43E6-A11A-509EADD01607

Q35185694-1A4BAE7D-172F-44A6-9CA4-68E47DFEA8E1

Q35185694-425C6F31-7811-4D62-A9FB-B8C58595644E

Q35185694-663D195B-8911-49E6-BEF9-35E7D539C055

Q35185694-99532DAC-CA68-4E8D-B862-B6201DD1A03D

P577

Q35185694-7547B7B7-27F5-48CA-B88E-5EC9F92119FC

P5875

Q35185694-B3020278-E33A-463D-AAA8-6CB07F009DCA

P698

Q35185694-69613160-BD70-4788-A1C6-B8EA1805B02A

P932

Q35185694-2ED9DA4F-26E9-4BD8-8CDF-90768714CA90

P356

J.JALZ.2014.07.001

P1433

Alzheimer's and Dementia

P1476

Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study.

@en

P2093

Galit Weinstein

http://www.w3.org/2001/XMLSchema#string

Ingmar Skoog

http://www.w3.org/2001/XMLSchema#string

Linda Younkin

http://www.w3.org/2001/XMLSchema#string

Philip A Wolf

http://www.w3.org/2001/XMLSchema#string

Rhoda Au

http://www.w3.org/2001/XMLSchema#string

Sarah Rosner Preis

http://www.w3.org/2001/XMLSchema#string

Steven Younkin

http://www.w3.org/2001/XMLSchema#string

Vincent Chouraki

http://www.w3.org/2001/XMLSchema#string

P2860

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

“Mini-mental state”

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond

Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

P304

249-57.e1

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JALZ.2014.07.001

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Charles Lambert

Lenore J Launer

P577

2014-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265658103

http://www.w3.org/2001/XMLSchema#string

P698

25217292

http://www.w3.org/2001/XMLSchema#string

P932

4362883

http://www.w3.org/2001/XMLSchema#string